UKUK

Matching cancers with drugs

11.12.2011

London – Cancer Research UK has begun recruiting patients in the first phase of its Stratified Medicine Programme, which is aimed at finding cancer biomarkers and establishing a genetic testing service in the UK. The charity’s multi-million pound programme ultimately hopes to establish a world-class National Health Service (NHS) genetic testing service for cancer patients in Britain.
The first phase will see the screening of tumour samples from up to 9,000 patients who have melanoma, breast, bowel, lung, prostate or ovarian cancer. It is to be funded by a £5.5m (€6.5m)contribution from the charity and its partners in industry – AstraZeneca and Pfizer. Patients will be asked to consent to allow a small sample of their tumour be sent to one of three leading NHS genetic testing labs. These are based at the Institute for Cancer Research in London, in Cardiff at the All Wales Regional Molecular Genetics Laboratory and at the West Midlands Regional Genetics Laboratory in Birmingham. There, researchers will extract the DNA from the sample and analyse it for a range of molecular variations linked to cancer.
The first phase is destined for completion in 2013. The initiative is closely aligned with the government-run Technology Strategy Board’s £6m (€7m) investment in the development of tests for analysing a tumour’s genetic profile, and its creation of secure software that can link this information to relevant clinical information. During the second phase, the charity plans to work with the UK Department of Health to develop a national system of genetic testing within the NHS. Cancer Research UK announced the plans for the programme last year.

UKUK

22.12.2011

London - Nothing is well if the end is not well. For Astra Zeneca the end of 2011 isn't well at all. A new anti-ovarian cancer drug and a planned antidepressant have underperformed in tests. As a result, AstraZeneca will take a...

UKUK

17.12.2011

Surrey – The UK government is investing an additional £80m (€93.5m) to fund continued development of the Institute for Animal Health (IAH) at Pirbright, an institute of the Biotechnology and Biological Sciences Research Council...

UKUK

15.12.2011

Rijeka/London – Allergies like asthma or psoriasis might arise from environmental toxins, suggest researchers from Rijeka University (Croatia) and King’s College (London). In mice, they identified a special population of T cells...

UKUK

13.12.2011

London – Interesting times ahead in the European cancer treatment market. A report states that in the UK alone, diagnosis and treatment costs are likely to increase by 62%, from £9.4 billion in 2010 to £15.3 billion by 2021. The...

UKUK

12.12.2011

York - Tissue Regenix Group plc plans to raise €29m through the sale of 181.8 million shares. The regenerative medical device company is held within the IP Group portfolio and a spin-out company from the University of Leeds. The...

UKUK

06.12.2011

London – British Prime Minister David Cameron is trying to come to the rescue of Britain’s embattled biopharmaceutical industry. He has earmarked €210m to support a “biomedical catalyst fund” to back early-stage academic and...

UKUK

06.12.2011

London - David Cameron plans to come to the rescue of Britain's embattled biopharmaceutical industry. The conservative prime minister has earmarked £180m (€210 million) to support a "biomedical catalyst fund" to back ...

UKUK

25.11.2011

Cancer Research UK has started recruiting patients in the first phase of its Stratified Medicine Program, which is seeking to find cancer biomarkers and establish a genetic testing service in the U.K. The charity's multi-million...

UKUK

24.11.2011

London – The European Medicines Agency has recalled all batches of the cancer drugs Busilvex, Velcade and Vidaza manufactured at Boehringer Ingelheim’s Ben Venue Laboratories facility in Bedford, Ohio, from the European market....

Displaying results 11 to 20 out of 396

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/1/article/matching-cancers-with-drugs.html

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%
  • MORPHOSYS75.99 EUR4.89%

FLOP

  • EPIGENOMICS4.15 EUR-4.38%
  • EVONIK26.20 EUR-2.42%
  • PAION2.80 EUR-2.10%

TOP

  • BIOFRONTERA2.82 EUR15.6%
  • BB BIOTECH166.45 EUR11.2%
  • HBM91.50 CHF8.6%

FLOP

  • MAGFORCE5.55 EUR-19.0%
  • PAION2.80 EUR-14.6%
  • CO.DON2.65 EUR-13.1%

TOP

  • SANTHERA89.00 CHF2182.1%
  • CO.DON2.65 EUR150.0%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 31.10.2014

Current issue

All issues